Investors

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in

Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment  No disease recurrences reported among responders after median follow up of more than 2 years Jemperli monotherapy could help eligible patients avoid

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA